F. Hoti

First name
F.
Last name
Hoti
Korhonen, P. ., Heintjes, E. M., Williams, R. ., Hoti, F. ., Christopher, S. ., Majak, M. ., … Bahmanyar, S. . (2016). Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. Bmj. http://doi.org/10.1136/bmj.i3903
Strongman, H. ., Korhonen, P. ., Williams, R. ., Bahmanyar, S. ., Hoti, F. ., Christopher, S. ., … Heintjes, E. M. (2017). Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2016-000364
Strongman, H. ., Christopher, S. ., Majak, M. ., Williams, R. ., Bahmanyar, S. ., Linder, M. ., … Hoti, F. . (2018). Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2017-000481
Heintjes, E. M., Bezemer, I. D., Prieto-Alhambra, D. ., Smits, E. ., Booth, H. P., Dedman, D. ., … van Beest, F. J. A. P.-. (2020). Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries. Clin Epidemiol. http://doi.org/10.2147/clep.s242065